Pyridostigmine Bromide Extended release Tablets, 180 mg
Rx Only

DESCRIPTION

Pyridostigmine bromide is an orally active cholinesterase inhibitor. Chemically, pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. Its chemical formula is C_9H_13BrN_2O_2, molecular weight 261.12. Its structural formula is:

![Structural formula of pyridostigmine bromide](image)

Pyridostigmine Bromide Extended release Tablets contain 180 mg pyridostigmine bromide. Inactive Ingredients: carnuba wax, zein, calcium phosphate, colloidal silicon dioxide, and magnesium stearate.

ACTIONS

Pyridostigmine Bromide Extended release Tablets inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine, but differs from it in certain clinically significant respects; for example, pyridostigmine is characterized by a longer duration of action and fewer gastrointestinal side effects.

INDICATION

Pyridostigmine Bromide Extended release Tablets is useful in the treatment of myasthenia gravis.

CONTRAINDICATIONS

Pyridostigmine Bromide Extended release Tablets is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.

WARNINGS

Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. As is true of all cholinergic drugs, overdosage of Pyridostigmine Bromide
Extended release Tablets may result in cholinergic crisis, a state characterized by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by extreme muscle weakness, and thus may be difficult to distinguish from cholinergic crisis on a symptomatic basis. Such differentiation is extremely important, since increases in doses of Pyridostigmine Bromide Extended release Tablets or other drugs of this class in the presence of cholinergic crisis or of a refractory or "insensitive" state could have grave consequences. Osserman and Genkins\textsuperscript{1} indicate that the differential diagnosis of the two types of crisis may require the use of edrophonium chloride as well as clinical judgment. The treatment of the two conditions obviously differs radically. Whereas the presence of myasthenic crisis suggests the need for more intensive anticholinesterase therapy, the diagnosis of cholinergic crisis, according to Osserman and Genkins,\textsuperscript{1} calls for the prompt withdrawal of all drugs of this type. The immediate use of atropine in cholinergic crisis is also recommended. Atropine may also be used to abolish or obtund gastrointestinal side effects or other muscarinic reactions; but such use, by masking signs of overdosage, can lead to inadvertent induction of cholinergic crisis.

For detailed information on the management of patients with myasthenia gravis, the physician is referred to one of the excellent reviews such as those by Osserman and Genkins,\textsuperscript{2} Grob\textsuperscript{3} or Schwab.\textsuperscript{4,5}

**Usage in Pregnancy**

The safety of Pyridostigmine Bromide Extended release Tablets during pregnancy or lactation in humans has not been established. Therefore, use of Pyridostigmine Bromide Extended release Tablets in women who may become pregnant requires weighing the drug's potential benefits against its possible hazards to mother and child.

**PRECAUTION**

Pyridostigmine is mainly excreted unchanged by the kidney.\textsuperscript{6,7,8} Therefore, lower doses may be required in patients with renal disease, and treatment should be based on titration of drug dosage to effect.\textsuperscript{6,7}

**Pediatric Use**

Safety and effectiveness in pediatric patients have not been established.

**ADVERSE REACTIONS**

The side effects of Pyridostigmine Bromide Extended release Tablets are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness. Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.

**DOSAGE AND ADMINISTRATION**

Each Pyridostigmine Bromide Extended release Tablet contains 180 mg pyridostigmine bromide. This form provides uniformly slow release, hence prolonged duration of drug action; it facilitates control of myasthenic symptoms with fewer individual doses daily. The immediate effect of a 180 mg Pyridostigmine Bromide Extended release Tablet is about equal to that of a 60 mg pyridostigmine bromide tablet; however, its duration of effectiveness, although varying in individual patients, averages 2½ times that of a 60 mg dose.
Dosage
The size and frequency of the dosage must be adjusted to the needs of the individual patient. One to three Pyridostigmine Bromide Extended release Tablets, 180 mg, once or twice daily, will usually be sufficient to control symptoms; however, the needs of certain individuals may vary markedly from this average. The interval between doses should be at least 6 hours. For optimum control, it may be necessary to use the more rapidly acting tablets or syrup in conjunction with Pyridostigmine Bromide Extended release Tablets therapy.

Note: For information on a diagnostic test for myasthenia gravis, and for the evaluation and stabilization of therapy, please see product literature on edrophonium chloride.

HOW SUPPLIED
Pyridostigmine Bromide Extended release Tablets, 180 mg, are supplied in bottles of 30 tablets, NDC 47781-335-30.

Pyridostigmine Bromide Extended release Tablets are available as a cream to yellow, capsule-shaped tablet, containing 180 mg pyridostigmine bromide, debossed “335” on one side and has functional scoring on the other side.

Storage
Store Pyridostigmine Bromide Extended release Tablets at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature]. Keep Pyridostigmine Bromide Extended release Tablets in a dry place with the silica gel (desiccant) enclosed.

Note: Because of the hygroscopic nature of the Pyridostigmine Bromide Extended release Tablets, mottling may occur. This does not affect their efficacy.

REFERENCES

Made in USA
Distributed by:
Alvogen, Inc.
Pine Brook NJ 07058 USA
PI335-00
NDC 47781-335-30

Pyridostigmine Bromide
EXTENDED-RELEASE TABLETS

Pharmacist: Dispense in the unit of use container.

180 mg

CAUTION: EXTREMELY MOISTURE SENSITIVE.
DO NOT REMOVE DESICCANT. CLOSE TIGHTLY.

Rx only
30 Tablets

Alvogen®

PYRIDOSTIGMINE BROMIDE
pyridostigmine bromide tablet, extended release

Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>NDC:47781-335</td>
</tr>
</tbody>
</table>

Route of Administration

<table>
<thead>
<tr>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORAL</td>
</tr>
</tbody>
</table>

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE - UNIE19Q69HH21)</td>
<td>PYRIDOSTIGMINE BROMIDE</td>
<td>180 mg</td>
</tr>
</tbody>
</table>

Inactive Ingredients
<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARNAUBA WAX (UNII: R12CBM0EIZ)</td>
<td></td>
</tr>
<tr>
<td>ZEIN (UNII: 80N308T1NN)</td>
<td></td>
</tr>
<tr>
<td>CALCIUM PHOSPHATE, UNSPECIFIED FORM (UNII: 97Z1W3NDX)</td>
<td></td>
</tr>
<tr>
<td>SILICON DIOXIDE (UNII: ETJ7Z6XBU4)</td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM STEARATE (UNII: 70097M63D0)</td>
<td></td>
</tr>
</tbody>
</table>

**Product Characteristics**

<table>
<thead>
<tr>
<th>Color</th>
<th>YELLOW</th>
<th>Score</th>
<th>2 pieces</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>CAPSULE</td>
<td>Size</td>
<td>19mm</td>
</tr>
<tr>
<td>Flavor</td>
<td></td>
<td>Imprint Code</td>
<td>335</td>
</tr>
<tr>
<td>Contains</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Packaging**

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:47781-335-30</td>
<td>30 in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>06/29/2015</td>
<td></td>
</tr>
</tbody>
</table>

**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA204737</td>
<td>06/29/2015</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Alvogen, Inc. (008057330)

**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norwich Pharmaceuticals, Inc.</td>
<td>132218731</td>
<td>analysis(47781-335), manufacture(47781-335), pack(47781-335)</td>
<td></td>
</tr>
</tbody>
</table>

Revised: 12/2019